`
`First Named Inventor: Rhett Mead SCHIFFMAN
`
`Confirmation No.: 4791
`
`Applicant: VISUS THERAPEUTICS, INC.
`
`Art Unit: To Be Assigned
`
`Application No.: 18/250,921
`
`371(c) Date: Jo Be Assigned
`
`(U.S. National Phase ofInt'l Appl. No.
`PCT/US2021/057720;
`
`IA Date: November 2, 2021)
`
`Examiner: 7o Be Assigned
`
`Atty. Docket: 4902.0110003
`
`Title: DEGRADANT COMPOUNDIN A MEDICAMENT
`
`Request for Corrected Official Filing Receipt
`
`Commissionerfor Patents
`PO Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`Mail Stop Missing Parts
`
`Applicant hereby requests that a corrected Official Filing Receipt be issued and sent to the
`
`undersigned representative. Specifically, the following corrections to the Official Filing Receipt are
`
`requested:
`
`In the Title section, please correct thetitle as follows:
`
`DEGRADANT COMPOUND IN A MEDICANT to DEGRADANT COMPOUND
`
`IN A MEDICAMENT
`
`Atty. Dkt. No. 4902.0110003
`
`
`
`Rhett Mead SCHIFFMAN
`Application No. 18/250,921
`
`In support of the above request, a marked-up copy of the instant Official Filing Receiptis
`
`enclosed to show the corrections and a corrected Application Data Sheet. It is requested that a
`
`corrected Official Filing Receipt be issued, and sent to the undersignedat the earliest possible time.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`/Marsha Rose Gillentine, Reg. No. 58,403/
`
`MarshaRose Gillentine
`Attorney for Applicant
`Registration No. 58,403
`
`Date:__November 28, 2023
`
`1101 K Street, NW
`10" Floor
`Washington, D.C. 20005
`Main: 202-371-2600
`21378889. 1
`
`Atty. Dkt. No. 4902.0110003
`
`